EMA Withdrawn: Provenge (autologous peripheral-blood mononuclear cells including a minimum of 50 million autologous CD54+ cells activated with prostatic acid phosphatase granulocyte-macrophage colony-stimulating factor) — Dendreon UK Ltd

View source ↗

Summary

Dendreon’s Provenge has been withdrawn in Europe, with the therapeutic area listed as prostatic neoplasms.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Prostate Cancer

Drugs mentioned

• PROVENGE (sipuleucel-T)

Snippet

Status: Withdrawn. Therapeutic area: Prostatic Neoplasms. MAH: Dendreon UK Ltd. Decision date: 06/05/2015